ArticleOncology letters2016
NRAGE promotes the malignant phenotype of hepatocellular carcinoma.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- CROST: a comprehensive repository of spatial transcriptomics.Nucleic acids research · 2024Article
- Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer.Cancer immunology, immunotherapy : CII · 2023Article
- AATF inhibition exerts antiangiogenic effects against human hepatocellular carcinoma.Frontiers in oncology · 2023Article
- NRAGE Confers Radiation Resistance in 2D and 3D Cell Culture and Poor Outcome in Patients With Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2022Article
- Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles.PloS one · 2019Article
- Observational
- From Neural Crest Development to Cancer and Vice Versa: How p75Frontiers in molecular neuroscience · 2018Review
- A seven-gene prognostic signature for rapid determination of head and neck squamous cell carcinoma survival.Oncology reports · 2017Article
- An integrated multigene expression panel to predict long-term survival after curative hepatectomy in patients with hepatocellular carcinoma.Oncotarget · 2017Article
- GPR155 Serves as a Predictive Biomarker for Hematogenous Metastasis in Patients with Gastric Cancer.Scientific reports · 2017Article
- Molecular mechanisms of peritoneal dissemination in gastric cancer.World journal of gastroenterology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a fatal disease, primarily due to the limited effective therapies available for patients with advanced or recurrent stages of the disease. Therefore, in order to improve patient prognosis, it is important to identify an informative biomarker for HCC progression, as well as a molecular target for therapy. Neurotrophin receptor-interacting melanoma antigen-encoding protein (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.